Aurinia Pharmaceuticals (NASDAQ:AUPH) Receives "Buy" Rating from HC Wainwright

Key Points

• HC Wainwright has initiated coverage on Aurinia Pharmaceuticals with a "buy" rating and a price target of $17.00, indicating a potential upside of 90.16% from the current stock price.
• The company recently reported earnings of $0.16 EPS, exceeding estimates, along with revenue of $62.47 million for the quarter, positioning it favorably in the market.
• Institutional investors hold 36.83% of Aurinia Pharmaceuticals' stock, with several hedge funds increasing their stakes in the company recently.

HC Wainwright reiterated their buy rating on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH - Free Report) TSE: AUP in a research note released on Wednesday morning, MarketBeat reports. HC Wainwright currently has a $17.00 price objective on the biotechnology company's stock. HC Wainwright also issued estimates for Aurinia Pharmaceuticals' Q2 2025 earnings at $0.16 EPS, Q3 2025 earnings at $0.18 EPS, Q4 2025 earnings at $0.19 EPS, FY2025 earnings at $0.69 EPS, Q1 2026 earnings at $0.18 EPS, Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.18 EPS, Q4 2026 earnings at $0.14 EPS, FY2026 earnings at $0.68 EPS, FY2027 earnings at $0.59 EPS, FY2028 earnings at $0.57 EPS and FY2029 earnings at $0.81 EPS.

Aurinia Pharmaceuticals Stock Up 13.5%

AUPH traded up $1.25 during trading hours on Wednesday, reaching $10.49. 7,741,610 shares of the stock traded hands, compared to its average volume of 2,348,305. The firm's fifty day simple moving average is $8.35 and its two-hundred day simple moving average is $8.14. The company has a market cap of $1.38 billion, a price-to-earnings ratio of 24.40 and a beta of 1.23. Aurinia Pharmaceuticals has a fifty-two week low of $5.20 and a fifty-two week high of $10.67. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The company had revenue of $70.01 million for the quarter, compared to the consensus estimate of $64.27 million. As a group, analysts forecast that Aurinia Pharmaceuticals will post 0.11 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Invesco Ltd. boosted its stake in Aurinia Pharmaceuticals by 1.0% during the 4th quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company's stock valued at $1,294,000 after acquiring an additional 1,421 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Aurinia Pharmaceuticals by 56.1% in the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after buying an additional 1,744 shares during the last quarter. Bridgefront Capital LLC lifted its position in shares of Aurinia Pharmaceuticals by 12.9% in the 4th quarter. Bridgefront Capital LLC now owns 16,606 shares of the biotechnology company's stock worth $149,000 after buying an additional 1,891 shares during the last quarter. Cetera Investment Advisers lifted its position in shares of Aurinia Pharmaceuticals by 3.2% in the 4th quarter. Cetera Investment Advisers now owns 64,638 shares of the biotechnology company's stock worth $580,000 after buying an additional 2,000 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its position in shares of Aurinia Pharmaceuticals by 5.9% in the 4th quarter. Teacher Retirement System of Texas now owns 36,098 shares of the biotechnology company's stock worth $324,000 after buying an additional 2,020 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.